A Phase 4 interventional study of Injectafer and Ferrous Sulfate tablets in Iron Deficiency Anemia Secondary to IBD or Gastric Bypass, sponsored by American Regent, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-17.
Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 19th largest by enrollment, is one of 2 that started in 2014, is one of 24 in phase 4, and was the 17th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
Hawler Medical University
Ages 18–45 · Women only
Zhaojian Niu,MD
Ages 18–75
Children's Hospital of Orange County
Ages 1–18
Liverpool Hope University
Ages 60–85
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 24
First in 2006; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 100 across the 57 interventional studies. Of the 45 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under American Regent, Inc., one of the names counted as Daiichi Sankyo. Under that name alone:
American Regent, Inc. is the lead sponsor of 53 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
13 studies in Anemia, Iron-Deficiency by Daiichi Sankyo: none open now, none under way, none of them phase 3. Of 11 finished, 10 (91%) have results posted.
Among the 13 studies in Anemia, Iron-Deficiency by Daiichi Sankyo, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 3 in phase 4, and was the 8th registered.
Daiichi Sankyo’s Anemia, Iron-Deficiency studies by the year they started, since 2009.
2 of the studies testing ferric carboxymaltose in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
| NCT07772453Zhaojian Niu,MDFerric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, from their registry updates:
Among Daiichi Sankyo’s 13 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron to baseline hepcidin levels to determine if any of these select IBD or Gastric Bypass patients may demonstrate to be inappropriate for oral iron therapy.
The primary objective of this study is to evaluate the treatment response of Injectafer vs. oral iron in patients with varying hepcidin levels correlating the treatment response/hepcidin levels to more common laboratory parameters such as ferritin and CRP (C-Reactive Protein) levels and possibly determine if any of these select IBD or Gastric Bypass patients may demonstrate to be inappropriate for oral iron therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of Injectafer, at 15 mg/kg for a maximum single dose of 750 mg given on Days 0 and 7 for a total of up to 1500 mg
Drug: Injectafer
Oral Ferrous Sulfate at 325 mg (1 tablet) three times a day for 28 days
Drug: Ferrous Sulfate tablets
2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
Also known as: Ferric Carboxymaltose (FCM)
325mg (1 tablet) three times a day for 28 days
Also known as: Oral Iron tablets
Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders).
Responders were defined as subjects achieving an increase from baseline ≥2 g/dL at anytime between baseline and the end of the study (Day 28). The relation between screening hepcidin and change in hemoglobin was assessed with regression models with baseline hepcidin and treatment group as independent factors. Treatment group differences (oral vs. IV iron) for mean changes in endpoints were assessed with the analysis of covariance with a fixed factor for treatment and baseline value as covariate. Treatment group differences for proportions were assessed with the normal approximation to the binomial distribution.
Time frame: anytime between baseline and end of study (day 28) or time of intervention
This study was conducted at 41 study centers in the United States. The first subject was screened on 06 February 2014 and the last subject was completed on 07 July 2016.
| Milestone | Injectafer | Ferrous Sulfate Tablets |
|---|---|---|
| Started | 100 | 98 |
| Completed | 92 | 85 |
| Not completed | 8 | 13 |
| Withdrew: Adverse event | 1 | 5 |
| Withdrew: Lost to follow-up | 2 | 3 |
| Withdrew: Study drug received outside protocol | 0 | 1 |
| Withdrew: Physician decision | 4 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 |
Responders were defined as subjects achieving an increase from baseline ≥2 g/dL at anytime between baseline and the end of the study (Day 28). The relation between screening hepcidin and change in hemoglobin was assessed with regression models with baseline hepcidin and treatment group as independent factors. Treatment group differences (oral vs. IV iron) for mean changes in endpoints were assessed with the analysis of covariance with a fixed factor for treatment and baseline value as covariate. Treatment group differences for proportions were assessed with the normal approximation to the binomial distribution.
| Participants | Injectafer | Ferrous Sulfate Tablets |
|---|---|---|
| Correlation Between Screening Hepcidin and Change in Hemoglobin From Baseline to Highest Observed Hemoglobin Change (Proportion of Responders). | 60 | 34 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Injectafer | 0/99 (0%) | 3/99 (3%) | 33/99 (33.3%) |
| Ferrous Sulfate Tablets | 0/97 (0%) | 1/97 (1%) | 24/97 (24.7%) |
| Event | Injectafer | Ferrous Sulfate Tablets |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 0/99 | 1/97 |
| Small intestinal obstructionGastrointestinal disorders | 0/99 | 1/97 |
| Colitis ulcerativeGastrointestinal disorders | 1/99 | 0/97 |
| Large intestinal obstructionGastrointestinal disorders | 1/99 | 0/97 |
| Clostridium difficile colitisInfections and infestations | 1/99 | 0/97 |
| Event | Injectafer | Ferrous Sulfate Tablets |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/99 | 10/97 |
| Blood phosphorous decreasedInvestigations | 10/99 | 0/97 |
| NauseaGastrointestinal disorders | 2/99 | 6/97 |
| Abdominal painGastrointestinal disorders | 1/99 | 5/97 |
| VomitingGastrointestinal disorders | 0/99 | 5/97 |
| HypophosphataemiaMetabolism and nutrition disorders | 5/99 | 0/97 |
| HeadacheNervous system disorders | 4/99 | 0/97 |
| Abdominal pain upperGastrointestinal disorders | 0/99 | 3/97 |
| DiarrhoeaGastrointestinal disorders | 0/99 | 3/97 |
| Faeces discouleredGastrointestinal disorders | 0/99 | 3/97 |
Of the 198 subjects randomized, two subjects (one in each group) were not treated.
| Age, Continuous(years) | Injectafer | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| Median | 38.3 (18.6 to 85.5) | 43.0 (18.5 to 74.3) | 40.5 (18.5 to 85.5) |
| Sex: Female, Male(Participants) | Injectafer | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| Female | 76 | 66 | 142 |
| Male | 23 | 31 | 54 |
| Race/Ethnicity, Customized(participants) | Injectafer | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| White | 72 | 79 | 151 |
| Black/African American | 25 | 17 | 42 |
| Asian | 1 | 1 | 2 |
| American Indian/Alaska Native | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Injectafer | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| United States | 99 | 97 | 196 |
| Point of Care Hemoglobin(g/dL) | Injectafer | Ferrous Sulfate Tablets | Total |
|---|---|---|---|
| Mean | 9.3 ± 1.19 | 9.4 ± 0.99 | 9.3 ± 1.10 |
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2014 to primary completion in Jul 2016, 30 months.
Results were first posted in Sep 2020, 4 years 2 months after primary completion.
Of 51 phase 4 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 30 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ferric carboxymaltose · Ferrous sulfate